AI-generated research brief — verify at source
Astegolimab Shows Inconsistent Exacerbation Reduction Across Two COPD Trials
In the phase 2b ALIENTO trial, biweekly subcutaneous astegolimab produced approximately 15% fewer moderate or severe COPD exacerbations per year compared with placebo (rate ratio 0.85, 95% CI 0.72–1.00; p=0.049), but the larger phase 3 ARNASA trial failed to replicate this result for the same dosing regimen (rate ratio 0.85, 95% CI 0.72–1.01; p=0.068), leaving the clinical utility of the drug uncertain despite numerically similar effect sizes across both programmes.
What Was Studied
These trials investigated whether astegolimab, a monoclonal antibody targeting the ST2 receptor for interleukin-33, could reduce the annualised rate of moderate or severe exacerbations in patients with COPD who experience frequent exacerbations. Critically, eligibility was independent of baseline blood eosinophil counts, meaning the drug was evaluated across both eosinophilic and non-eosinophilic disease phenotypes — a feature that distinguishes this programme from biologic trials restricted to high-eosinophil populations.
How It Was Studied
ALIENTO (phase 2b) and ARNASA (phase 3) were randomised, double-blind, placebo-controlled trials enrolling current or former smokers with COPD and a documented history of frequent exacerbations. Together the two trials enrolled 2,676 participants (ALIENTO n=1,301; ARNASA n=1,375), randomised 1:1:1 to subcutaneous astegolimab 476 mg every 2 weeks, astegolimab 476 mg every 4 weeks, or placebo, all on a background of optimised inhaled maintenance therapy. Stratification was by smoking status and geographic region, and treatment continued for 52 weeks. The primary endpoint was analysed in all participants who received at least one dose, with missing data handled by assuming similarity to participants sharing the same treatment group and baseline characteristics.
What Was Observed
- ALIENTO biweekly dosing met its primary endpoint: astegolimab every 2 weeks was associated with roughly 15% fewer annual exacerbations than placebo — a statistically significant though borderline reduction (rate ratio 0.85, 95% CI 0.72–1.00; p=0.049). The every-4-week regimen in the same trial showed a smaller, non-significant reduction of about 7% (rate ratio 0.93, 95% CI 0.79–1.10; p=0.38).
- ARNASA did not meet statistical significance for its primary biweekly arm: despite a numerically identical point estimate to ALIENTO, the phase 3 result for every-2-weeks dosing crossed the null (rate ratio 0.85, 95% CI 0.72–1.01; p=0.068). The every-4-week arm in ARNASA did reach significance, with approximately 18% fewer exacerbations (rate ratio 0.82, 95% CI 0.70–0.98; p=0.024), though this was not the pre-specified primary analysis for that trial.
- The safety profile appeared acceptable and balanced across groups: the proportion of participants experiencing at least one adverse event was high across all arms — 84.0% in ALIENTO and 85.5% in ARNASA — but was evenly distributed between active treatment and placebo. Deaths occurred in 3.1% of ALIENTO participants and 3.2% in ARNASA, with only three deaths across both trials (0.1%) considered by investigators to be treatment-related.
Why This Matters
COPD exacerbations drive disease progression and represent a major unmet need in patients who continue to exacerbate despite optimised inhaled therapy. These trials tested the hypothesis that blocking the IL-33/ST2 pathway — implicated in both neutrophilic and eosinophilic inflammatory mechanisms — could benefit a broad, phenotype-unselected COPD population. The pattern of results, while inconsistent, suggests that this pathway may play a contributory role in exacerbation biology across eosinophil strata, though the magnitude of benefit observed remains modest and its reproducibility is now in question.
How to Read This Result
Although both trials were well-designed and large, the failure of the pivotal phase 3 trial to confirm the primary endpoint for the biweekly regimen — despite a numerically identical effect size — introduces substantial uncertainty about whether the observed reductions reflect a true treatment effect or statistical variability around a small signal.
Limitations
The most consequential limitation is the inconsistency in statistical significance across trials and dosing regimens: the pre-specified primary endpoint was met only in ALIENTO for the every-2-week dose (p=0.049) and in ARNASA for the every-4-week dose (p=0.024), with no single regimen achieving significance in both trials simultaneously. The primary missing-data assumption — that absent observations resemble those of participants with matching baseline characteristics within the same treatment arm — introduces a degree of imputation uncertainty that cannot be fully verified. The marginal p-value in ALIENTO (p=0.049) also warrants caution, as it sits at the conventional threshold and the confidence interval just touches 1.00.